What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Pharmaceutical form: Solution for infusion; Route of administration: Subcutaneous”In the company’s words, NCT07297329 on ClinicalTrials.gov
- Tested for
- Multiple Myeloma (MM), Amyloidosis, Systemic Lupus Erythematosus (SLE), IgA Nephropathy, Relapsed or Refractory Hematologic Malignancies
- Main trialPhase 3
- “The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free survival (PFS) and/or improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.”In the company’s words, NCT07297329 on ClinicalTrials.gov
Other drugs for Multiple Myeloma (MM)
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up4
- Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Sep 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2027 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | |
| Phase 3Recruiting | Dec 2027 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA) | |
| Phase 1/2Not yet recruiting | Apr 2027 | A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus | |
| Phase 1/2Not yet recruiting | Sep 2027 | A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases | |
| Phase 1Recruiting | 28 Aug 2025 | A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026